CTT: Marktkapitalisierung 12 Mio. / Einnahmen demnächst 20 Mio. bis 50 Mio. jährlich ? - 500 Beiträge pro Seite

[married]

Man beachte die geringe Marktkapitalisierung dieser Gesellschaft von derzeit nur 12 Mio. $ !

Erwartet werden revenues von 25 Mio. bis 50 Mio. jährlich in/ab den Jahren 2009 bzw. 2010 ff.

In diesen news hat am 24.02.2009 CTT seit langem wieder ein Mal auf sich aufmerksam gemacht:

Fairfield, CT - (February 24, 2009) - Competitive Technologies, Inc. (NYSE Alternext US: CTT) announced today that it has signed an agreement with Life Epistéme srl granting them exclusive distribution rights in each of 29 countries throughout Europe, Asia, Africa, the Middle East, South America and Oceania for CTT's pain management medical device. The device is a non-invasive method for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs.
"We have seen this innovative device successfully used in Italy, and are proud to be able to bring it to other patients around the world," said Dr. Domenico Pecorini, one of the founders of Life Epistéme. "The population in the countries included in our contract totals over 1.7 billion people, about 25% of the world's population. Our network of distributors in strategic centers around the world will facilitate the delivery process for the device."
"Life Epistéme provides CTT with a strong and effective global partner," said John B. Nano, CTT's Chairman, President and CEO. "This represents a remarkable opportunity for our innovative pain management medical device. Our exclusive signed distribution agreements for this device now cover over 45% of the world's population and the contractual minimums have a retail sales value of over $25 million for 2009 and about $50 million for 2010. CTT will share in revenue derived from sales of the device to our distributors and both CTT and our distributors expect sales to exceed the contract minimums."

http://www.competitivetech.net/


><

[married]

Gestern nun ein Kurssprung von 27 % ( bei 15-fachem Tagesumsatz ) nach diesen news, die CTT auch den Markt in den USA erschließen:

Competitive Technologies Receives FDA Authorization for Sales of Pain Therapy Medical Device

Wednesday February 25, 9:38 am ET

FAIRFIELD, Conn., Feb. 25, 2009 (GLOBE NEWSWIRE) -- Competitive Technologies, Inc. (NYSE Alternext US:CTT) announced today that the US Federal Drug Administration (FDA) has issued a 501(k) letter of authorization allowing US sales of CTT's pain therapy medical device. The device is a non-invasive method for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs. The FDA authorization expands CTT's opportunities for sales in both the US and globally. CTT has exclusive worldwide rights to this patented device. The CTT device also has Medical Device CE certification from the European Union allowing sales throughout Europe and several other countries.

http://biz.yahoo.com/pz/090225/160320.html


><

[married]

Darüber hinaus hier noch das restliche Portfolio von CTT:

Technologies Available for Licensing

Life Sciences

Unitary Anastomotic Device (UAD)
Breast Cancer Test
Bone Biomaterial
Lupus Diagnostic and Monitoring Technology
Endogenous Opioid Peptides
Cobalamin and Folic Acid Deficiencies
Insulinotropic Peptide as an Osteotropic Hormone
Green Tea Formulations
LTP Autoimmune Therapeutic
Neuroprotection and Cognitive Enhancement
Sexual Dysfunction Therapeutic
Skin Pigment Enhancer
Wound Sealant

Physical Sciences

Solar Power
Fiber Mixed Red-Green-Blue White Emitting LED Package
Large Area Plasma Display
Preparation of Ordered Multi-Layer Films
Radiation Curable Coatings
Silica Thin Films
Light Controlled Vapor Deposition

Applied Sciences

MC Square Light and Sound System
Radio Alert Emergency Warning System (RAWS)
Structural Steel Fissure Detection Paint
Compressed Air Drying Device
High-Power Atomizer
Public Key Encryption
Vehicle Rapid Deceleration Warning Device
Growing Single Crystals
Hydrolase Surfactant Systems
Video Compression and MPEG-4
Liquid Enzyme Pre-Wash Composition - 1
Liquid Enzyme Pre-Wash Composition - 2
Vehicle Rollover Warning System
Stable Liquid Aqueous Oxidant Detergent
Mobile Washing Unit for Limited Mobility Individuals

http://www.competitivetech.net/technologies/full-portfolio.h…

P.S. Ich verstehe diese ( meine ) postings als reine Diskussionsbeiträge bei w : o und nicht als Kaufempfehlung.


><

[seblas]

Antwort auf Beitrag Nr.: 36.655.268 von married am 26.02.09 07:55:45

Competitive Technologies Inc. (CTT)1.50 sehr stark ... top, SO exp.

[married]

Antwort auf Beitrag Nr.: 36.659.015 von seblas am 26.02.09 14:51:53

Nun gilt es den ersten großen Partner in den Staaten an Land zu ziehen. Weitere könnten folgen und jedes Mal sollte / könnte CTT mit einer news dazu aufwarten. Langweilig sollte es die nächsten Wochen nicht werden.

Die in den Staaten geäußerten Kurserwartungen in Richtung 15.00 Dollar halte ich jedoch im Moment noch für übertrieben.

FAIRFIELD, Conn., Feb. 26, 2009

The interview is focused on the FDA 510(k) letter of authorization allowing U.S. sales of CTT's pain therapy medical device. The device is a non-invasive method for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs. In the interview, Mr. Nano points out that CTT expects the new medical device to produce revenue and profits larger than any other technology in CTT's 40 year history. Further, when CTT had strong sales and earnings, the CTT stock traded at over $15 per share producing a market capitalization over $120 million, over 10 times the current $12 million.


The CTT device also has Medical Device CE certification from the European Union allowing sales of the device throughout Europe and several other countries. CTT has exclusive worldwide rights to this patented device. CTT has recently signed an agreement with Life Episteme srl granting them exclusive distribution rights in 29 countries throughout Europe, Asia, Africa, the Middle East, South America and Oceania. Earlier country-exclusive distribution rights have been granted to Excel Life Sciences, Inc. for India, to GEOMC Co., Ltd. for Korea, to AG Healthcare for Malaysia, and to Biogene Pharma Limited for Bangladesh. The review and selection process for additional distributors in other countries is continuing.


http://biz.yahoo.com/pz/090226/160432.html


><

[Carlito78]

Getmobile: Marktkapitalisierung 9 Mio. Einnahmen 100 Mio.

[married]

Und wer glaubt CTT sei nur in der genannten Schmerztheraphie engagiert, für den hier diese Auflistung:

Technologies Available for Licensing

Life Sciences

Pain Management Therapy
Unitary Anastomotic Device (UAD)
Breast Cancer Test
Bone Biomaterial
Lupus Diagnostic and Monitoring Technology
Endogenous Opioid Peptides
Cobalamin and Folic Acid Deficiencies
Insulinotropic Peptide as an Osteotropic Hormone
Green Tea Formulations
LTP Autoimmune Therapeutic
Neuroprotection and Cognitive Enhancement
Sexual Dysfunction Therapeutic
Skin Pigment Enhancer
Wound Sealant

Physical Sciences

Solar Power
Fiber Mixed Red-Green-Blue White Emitting LED Package
Large Area Plasma Display
Preparation of Ordered Multi-Layer Films
Radiation Curable Coatings
Silica Thin Films
Light Controlled Vapor Deposition

Applied Sciences

MC Square Light and Sound System
Radio Alert Emergency Warning System (RAWS)
Structural Steel Fissure Detection Paint
Compressed Air Drying Device
High-Power Atomizer
Public Key Encryption
Vehicle Rapid Deceleration Warning Device
Growing Single Crystals
Hydrolase Surfactant Systems
Video Compression and MPEG-4
Liquid Enzyme Pre-Wash Composition - 1
Liquid Enzyme Pre-Wash Composition - 2
Vehicle Rollover Warning System
Stable Liquid Aqueous Oxidant Detergent
Mobile Washing Unit for Limited Mobility Individuals


><

[married]

Als kleiner Zwischeninformation hier die Kopie der Antwort einer Mailanfrage an J.D.Johnson.

( Nur z.K. - ohne Wertung meinerseits - und der Hinweis auf die derzeitige Marktkapitalisierung CTT's von rund 11,5 Mio. )

Dear Mr. xxxx,

We are reviewing our options for distribution in the U.S. and will issue a press release announcing any material information regarding this important device.

We have signed distribution agreements for 35 countries overseas covering over 48% of the world's population. These contracts for the device have contractual minimuns for retail sales value of over $25 million for 2009 and about $50 million for 2010. CTT will share in revenue derived from sales of the device to distributors. The distributors expect actual sales to exceed the contract minimums.

Additional information about the company and this device can be found on CTT's website at www.competitivetech.net, and at www.CalmareTT.com for additional data on the device.

Please feel free to call me if you have any questions.

Johnnie

Johnnie D. Johnson
860 434 2465

http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks…

.

[lerchengrund]

Antwort auf Beitrag Nr.: 36.815.920 von married am 20.03.09 21:38:56

Ist der CRB-Index niedriger als vor einem Jahr, liegt keine Inflation vor. Und das bedeutet ein positives Signal für Aktien. Liegt der Index hingegen höher und ist auch noch schnell gestiegen, spricht das für Inflation und gegen einen Aktienkauf

[married]

Antwort auf Beitrag Nr.: 37.042.163 von lerchengrund am 26.04.09 12:56:14

spricht das für Inflation und gegen einen Aktienkauf



Stimmt nicht ganz ....

Gold - und / oder Silberminenaktien
können / sollten dann gekauft werden !


><

[lerchengrund]

Antwort auf Beitrag Nr.: 37.042.262 von married am 26.04.09 13:53:05

bei Ctt kann man eigentlich auch nichts falsch machen - oder?

[married]

Antwort auf Beitrag Nr.: 37.042.425 von lerchengrund am 26.04.09 15:24:07

Man kann bei jeder Aktie etwas falsch machen.

Aber die Chance auf 500 - 1000 % Kurschance
bei auf 100 % begrenztem
Kursriskio lockt schon.


><

[lerchengrund]

Antwort auf Beitrag Nr.: 37.042.571 von married am 26.04.09 16:59:59

wie sicher bist du dir da?

(100% ?)

[married]

Antwort auf Beitrag Nr.: 37.042.631 von lerchengrund am 26.04.09 17:29:58

Ja,

ich bin mir zu 100 % sicher bei dem

Kurs(verlus-)risiko von höchstens 100 %

[lerchengrund]

Antwort auf Beitrag Nr.: 37.043.125 von married am 26.04.09 19:58:25

99,9%?

[married]

Wenn Insider kaufen ......

Buy(P) /
Sell(S) P/S date Filed Date Company Symbol Insider Relationship Share Amt. Unit Price Total Proceeds Shares Owned Return(1m) Details

P 2009-04-21 2009-04-27 15:03:38 COMPETITIVE TECHNOLOGIES INC CTT Evans Joel M director 7,979 $1.13 $9,000.31 16,779 view

P 2009-04-21 2009-04-27 15:00:51 COMPETITIVE TECHNOLOGIES INC CTT Hornidge Richard D director 8,865 $1.13 $9,999.72 88,865 view

P 2009-04-21 2009-04-27 14:57:20 COMPETITIVE TECHNOLOGIES INC CTT Reali William L director 8,865 $1.13 $9,999.72 21,865 view

P 2009-04-21 2009-04-27 14:52:24 COMPETITIVE TECHNOLOGIES INC CTT HOWARD RUSTIN R director 8,865 $1.13 $9,999.72 34,865 view

P 2009-04-21 2009-04-27 14:49:10 COMPETITIVE TECHNOLOGIES INC CTT NANO JOHN B CEO 8,865 $1.13 $9,999.72 31,048 view


><

[married]

Gut sieht das aus:





Vor allem wenn man berücksichtigt, dass diese Aktie schon über 25.00 notierte bei nicht annähernd so guten Aussichten wie heute.

[married]

.



Heute wieder im Plus ( + 17 % ) .... man kann nicht meckern.




><

[lerchengrund]

Antwort auf Beitrag Nr.: 37.058.102 von married am 28.04.09 22:16:15

da tut sich was !

[married]

Antwort auf Beitrag Nr.: 37.080.978 von lerchengrund am 01.05.09 21:17:21

Stimmt,

aber nicht weitersagen.

Wir beide wollen doch die einzigen
deutschen Investierten in CTT
sein ( vorerst noch ) !





.

[lerchengrund]

Antwort auf Beitrag Nr.: 37.093.205 von married am 04.05.09 20:17:17

NEIN - ES SOLLEN ALLE WISSEN UND NACHKAUFEN ! DAS HILFT DOCH DEM KURS NACHHALTIG !

[married]

Antwort auf Beitrag Nr.: 37.094.939 von lerchengrund am 04.05.09 23:43:50

Das sehe ich nicht so.

Nach ersten Zahlungseingängen ( bei CTT ) will ich mir evtl. Nachkäufe ( preiswert ) offenhalten.


><

[married]

><


Nun sollten aber so langsam auch die zum Kursverlauf passenden news kommen:



.

[married]

Antwort auf Beitrag Nr.: 37.103.382 von married am 05.05.09 22:08:55

Wem inzwischen sein Depotanteil in CTT
zu groß geworden ist
kann ja einen Teil in Rohstoffwerte / einen Explorer
umswitchen, z.B. in CARDERO ( CDU ).
Hier werden bis Mitte Mai 2009 news
erwartet, welche die Zukunft des Unternehmens
( und der Aktie ) prägen werden.
Ich selbst bin dort bereits investiert
( als Diversifizierung zu CTT und VOCL ).

Und wenn es nicht klappen sollte ...
kann man ja vielleicht steuerliche Vorteile
( Verlust - Verrechnung mit CTT und VOCL - Gewinnen)
mitnehmen.


><

[lerchengrund]

Antwort auf Beitrag Nr.: 37.112.450 von married am 06.05.09 20:10:51

sind das Insiderinfos?

[married]

Antwort auf Beitrag Nr.: 37.113.605 von lerchengrund am 06.05.09 22:05:30

Nein ...

siehe einfach in den CDU - thread

Viel Glück !

[lerchengrund]

Antwort auf Beitrag Nr.: 37.113.733 von married am 06.05.09 22:18:45

was ist CDU thread?

[married]

Antwort auf Beitrag Nr.: 37.113.750 von lerchengrund am 06.05.09 22:20:06

Hier:

http://www.wallstreet-online.de/diskussion/862174-1-10/carde…

[lerchengrund]

Antwort auf Beitrag Nr.: 37.113.791 von married am 06.05.09 22:24:36

thanks!

[married]

Heute " benimmt " sich CTT endlich ein Mal wie eine normale Aktie.
Alles andere wäre ungesund ( geworden ).


><

[lerchengrund]

Antwort auf Beitrag Nr.: 37.122.816 von married am 07.05.09 19:29:00

wird auch Zeit!

[married]

Antwort auf Beitrag Nr.: 37.135.478 von lerchengrund am 09.05.09 07:25:15

Heute aber nochmals ein interessanter
( Nach- ) Kauf Tag zu 1,62 € in D. ?

Erste Kaufempfehlung(en) in USA.


><

[married]

@ lerchengrund ...

noch alle shares beisammen ?

Wo ist dein Ziel ?


><



.

[married]

Na, da konnte man als Mitleser
heute
auch wieder 20 % machen

[married]

Schluss 2.70

lerchengrund
dir hat es doch nicht
deshalb die Sprache verschlagen ?



( Das sind wir die letzte Zeit doch gewohnt )

[lerchengrund]

Antwort auf Beitrag Nr.: 37.149.078 von married am 11.05.09 22:05:18

ja, ich bin immer noch dabei!

[lerchengrund]

Antwort auf Beitrag Nr.: 37.149.078 von married am 11.05.09 22:05:18

[married]

Antwort auf Beitrag Nr.: 37.149.548 von lerchengrund am 11.05.09 22:59:46

Ich glaube unsere beiden Darstellungen von gestern abend
waren nicht aktuell.

Hier besser:

[married]

Antwort auf Beitrag Nr.: 37.150.117 von married am 12.05.09 07:23:28

( Sorry, Barchart com. ändert laufend seine Darstellungen )


Hier besser:





><

[lerchengrund]

Antwort auf Beitrag Nr.: 37.150.204 von married am 12.05.09 07:55:21

sooooo schön!

[lerchengrund]

Antwort auf Beitrag Nr.: 37.170.209 von lerchengrund am 13.05.09 22:10:08

Competitive Technologies Announces New Patent for Nanoparticle Bone Biomaterial
May 12, 2009
CTT Establishes U.S. Leasing Unit for Medical Device Sales
Fairfield, CT - (May 12, 2009) - Competitive Technologies, Inc. (NYSE Amex: CTT) announced today that its bone nanoparticle biomaterial technology has been issued a third patent supporting the first two patents and providing additional claims regarding the preparation of the primary components of the bone cement. CTT has an exclusive agreement with the University of South Carolina Research Foundation (USCRF) to license and commercialize the injectable, flowable, fast-curing, calcium phosphate-based nanotechnology biomaterial developed by Dr. Brian R. Genge, a research professor in the Department of Chemistry and Biochemistry at USC.

CTT's licensee for human spinal applications of the bone biomaterial, Soteira Inc., completed a third fund raise providing Soteira a total of approximately $24 million and access to an additional $6 million. Soteira is using the funds on their program to gain U.S. FDA and European CE Mark clearance for sales of the bone biomaterial. CTT has the opportunity to offer licenses to the bone biomaterial for other skeletal applications, as well as dental and veterinary repairs.

CTT also announced the development of a financing unit, Competitive Technologies Financial Services (CFS), which offers customers opportunities for leasing of CTT's pain therapy medical device in the U.S. market.

"This blockbuster medical device treats pain without the harmful side effects of most drugs, including morphine," said John B. Nano, CTT's Chairman, President and CEO. "This technology brings CTT to the forefront in providing a solution to the needs of patients and the improvement of palliative healthcare in the U.S. and internationally. It is a prime example of our strategy to connect clinical science to patient care. We believe that revenue and profits from the pain therapy technology will significantly increase CTT's market capitalization.

"The establishment of CFS allows our U.S. hospitals, clinics and medical practices to purchase the device directly, or to lease it over periods of time ranging from 24 - 60 months. In this difficult economic climate, CFS, created through an agreement with Americorp Financial, LLC (AFS), allows greater flexibility for these customers in managing their organization's cash flow. Upon execution of each lease, CTT will receive the full sales price of the device, while AFS carries the lease."

In early June, Mr. Nano, as the guest of the Italian government, will be co-moderating a roundtable discussion in Rome, Italy with Prof. Giuseppe Marineo, the developer of the pain therapy technology. Participants in the roundtable will include scientific and medical professionals from Europe, the U.S., Singapore, the UAE and Australia.

The breakthrough medical device is a non-invasive method for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs. The device has U.S. FDA 510(k) clearance for U.S. sales, as well as Medical Device CE certification from the E.U. allowing sales throughout Europe and several other countries. CTT has exclusive worldwide rights to this device.

Mr. Nano added, "In many cases, the non-invasive use of our innovative device allows the patient to avoid or reduce the use of drugs. In turn, this reduces the multiple adverse side effects of the drug use, including addiction, depression, drowsiness and collateral damage to other organs. Several studies report that nearly 10% of adults in the U.S. suffer from moderate-to-severe pain, with over 50% experiencing chronic or recurrent pain. The U.S. market for prescription pain drugs, the prevailing treatment for pain management, is nearly $5.0 billion, with nearly half for treatment of cancer pain, and about 40% for orthopedic pain, including lower back pain. Our device also treats neuropathic pain, the result of nerve damage, which is difficult to treat with traditional pain medications."

Developed in Italy by CTT's client, Prof. Marineo, the pain therapy technology was brought to CTT through the efforts of the Zangani Investor Community™. The unit, with a biophysical rather than a biochemical approach, uses a multi-processor able to simultaneously treat multiple pain areas by applying surface electrodes to the skin. CTT's partner, GEOMC Co. Ltd. of Korea is manufacturing the device commercially for worldwide distribution. For more information on the device, visit www.CalmareTT.com.

The device has been used on over 3,000 patients in Europe, including at the Pain Management Center at Tor-Vergata University Medical Center in Rome (http://www.ptvonline.it/uo_ter_ant_ing.asp).

[married]

Antwort auf Beitrag Nr.: 37.170.209 von lerchengrund am 13.05.09 22:10:08

.... kann Börse sein.

War das nun gestern ein

fill the gaps and buy the dips ?

Nochmals ... seit unserem Einstieg:




><

[married]

Antwort auf Beitrag Nr.: 37.170.226 von lerchengrund am 13.05.09 22:12:04

Sehr schön.

Die "Produktpalette" kann nicht breit genug sein.
Diversifizierung bleibt bei CTT ein Trumpf !


><

[married]

Aus SeekingAlpha:


This next company, Competitive Technologies (CTT), is much closer to fruition. From the prospectus:

The Company is a full service technology transfer and licensing provider. It provides technology transfer, selling and licensing services focused on the technology needs of its customers, matching those requirements with commercially viable technology solutions, bridging the gap between market demand and raw innovation.

CTT recently obtained sales and marketing rights from Native Energy, innovator of a non-invasive device for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs. With US government agencies alone, CTT has guaranteed contracts of $25M for 2009 and $50M for 2010, both of which are expected to be exceeded. CTT has worldwide distribution rights and is mass-producing the device with Korean partner GEOMC. The device has FDA 510(k) status, CE certification from the Europian Union and has been used on over 3,000 patients in Europe.

Insider buying has been rampant of late and the stock is climbing sharply. CTT has seen almost no revenue since 2006, shrinking its market cap to under $20M. That should grow significantly once sales of this device are reported.

Finally, I suspect that the new administration will be a good change for small defense companies on the cutting edge. Friendships and loyalty with the likes of Halliburton (HAL) have been reduced and the defense budget will do its part in "spreading the wealth."

Mehr unter

http://seekingalpha.com/article/136686-two-nanotech-companie…

[lerchengrund]

Antwort auf Beitrag Nr.: 37.174.344 von married am 14.05.09 13:07:55

guter newsflow!

[married]

Antwort auf Beitrag Nr.: 37.188.095 von lerchengrund am 15.05.09 20:02:49

Mit 2,75 weiterhin sehr stabil.

Wir brauchen nun erste Erfolge / Abschlüsse in den Staaten.

(Sonst wird das nichts mit den 10.00 $ )


><

[married]

Sie konsolidert weiter
auf hohem Niveau.
Das ist gesund.



.

[lerchengrund]

Antwort auf Beitrag Nr.: 37.223.269 von married am 20.05.09 22:03:56

Die Aktie hat einiges nachzuholen. Lassen wir Sie laufen!!!

[married]

Antwort auf Beitrag Nr.: 37.224.054 von lerchengrund am 21.05.09 00:20:29

could result in a dramatic increase in the stock's price as new investors take a position.

So langsam sollten wir in den Focus der Institutionellen rücken ....

..... wenn es nach dem heutigen Artikel geht:


Competitive Technologies: FDA-Approved Medical Device Hitting the Revenue Line
by: David Greene November 09, 2009 | about: CTT
David Greene


Competitive Technologies (CTT) is begining to see revenues generated as a result of the FDA approval of its very promising chronic pain mangement medical device. The company has already announced orders for 70 units and will recognize revenue for 17 units shipped in the past quarter (ending Oct. 31).

Five insiders, including the CEO, took advantage of the permitted window for insider purchaes last week and added to their holdings, despite the stock's 80% appreciation YTD.

CTT is also on the screens of mutual funds and money managers, with 6% of the shares outstanding held by institutions--enough to know that a few investment professionals are aware of CTT, but are clearly not fully invested should CTT exhibit progress in their business plan of expanding the market for their newly approved device. In other words, there is alot more room for adding to their positions with their holdings representing a very modest 6% now, than if the institutions were holding 60% of the shares O/S.

CTT's medical technology involves a non-invasive method for the rapid treatment of intense oncologic and neuropathic pain, including pain resistant to morphine and other traditional pain management drugs. CTT's device is currently in clinical trials for chemotherapy-induced pain and expects to be able to announce the results of the patient trials in the near future.

Investors should monitor CTT for future news on sales, increases in institutional ownership and trading volume increases. With only 10.24 Million shares outstanding, any increased exposure to the investment world could result in a dramatic increase in the stock's price as new investors take a position.

Disclosure: Long CTT

http://seekingalpha.com/article/172137-competitive-technolog…

[lerchengrund]

Antwort auf Beitrag Nr.: 38.347.051 von married am 09.11.09 12:46:33

[married]

Antwort auf Beitrag Nr.: 38.391.423 von lerchengrund am 15.11.09 22:04:52

Wer an die Story glaubt
kauft jetzt ( nach ).

Wenn die ersten Millionen eingehen ist es zu spät.


><

[sakura]

Antwort auf Beitrag Nr.: 38.391.892 von married am 16.11.09 07:45:56

für CIT kommt Alles zu spät, das wird nicht mehr

[married]

Antwort auf Beitrag Nr.: 38.394.270 von sakura am 16.11.09 14:11:11

Wer oder was ist CIT ?

[lerchengrund]

Antwort auf Beitrag Nr.: 38.396.953 von married am 16.11.09 18:25:11

Competitive Technologies (CTT) is begining to see revenues generated as a result of the FDA approval of its very promising chronic pain mangement medical device. The company has already announced orders for 70 units and will recognize revenue for 17 units shipped in the past quarter (ending Oct. 31).

Five insiders, including the CEO, took advantage of the permitted window for insider purchaes last week and added to their holdings, despite the stock's 80% appreciation YTD.

CTT is also on the screens of mutual funds and money managers, with 6% of the shares outstanding held by institutions--enough to know that a few investment professionals are aware of CTT, but are clearly not fully invested should CTT exhibit progress in their business plan of expanding the market for their newly approved device. In other words, there is alot more room for adding to their positions with their holdings representing a very modest 6% now, than if the institutions were holding 60% of the shares O/S.

CTT's medical technology involves a non-invasive method for the rapid treatment of intense oncologic and neuropathic pain, including pain resistant to morphine and other traditional pain management drugs. CTT's device is currently in clinical trials for chemotherapy-induced pain and expects to be able to announce the results of the patient trials in the near future.

Investors should monitor CTT for future news on sales, increases in institutional ownership and trading volume increases. With only 10.24 Million shares outstanding, any increased exposure to the investment world could result in a dramatic increase in the stock's price as new investors take a position.

Disclosure: Long CTT




Related Articles
Spectrum Pharma: Zevalin Sales Ramp Up Nov 22, 2009 Expiration Trade Behind Osiris Activity Nov 20, 2009 BioMed News Bytes: AstraZeneca, Delcath, Unilife Nov 20, 2009 A Possible New Indication for Progenix's Relistor Could Revive Its Fortunes Nov 20, 2009 Santarus' Zegrid Facing Back-to-Back FDA Approval Dates Nov 20, 2009 Related Stocks:CTT Investing Ideas
Get a daily email of Long Ideas,
Short Ideas, Cramer's Picks and
more.

We don't spam
Add Your Comment

Your Website/Blog (optional)Comment: Submitting comment, please wait ...Most Popular

[lerchengrund]

Antwort auf Beitrag Nr.: 38.434.531 von lerchengrund am 22.11.09 21:24:40

[married]

Antwort auf Beitrag Nr.: 39.449.791 von lerchengrund am 04.05.10 09:41:03

Da kann man Gewinne mitnehmen.

[lerchengrund]

Antwort auf Beitrag Nr.: 39.451.820 von married am 04.05.10 13:42:35

ist ja wahnsinn?

und alles ohne Nachrichten?

[married]

Antwort auf Beitrag Nr.: 39.518.943 von lerchengrund am 14.05.10 10:25:59

Nun ,

doch die Technik wird so langsame von der breiten Masse akzeptiert.

[lerchengrund]

Antwort auf Beitrag Nr.: 39.520.640 von married am 14.05.10 13:44:12

hoffentlich spricht sich es weiter rum.

[lerchengrund]

Antwort auf Beitrag Nr.: 39.539.909 von lerchengrund am 18.05.10 16:07:47

weiter so.

[alex63]

nich viel los hier, seltsam

[alex63]

Zitat von married: Man beachte die geringe Marktkapitalisierung dieser Gesellschaft von derzeit nur 12 Mio. $ !

Erwartet werden revenues von 25 Mio. bis 50 Mio. jährlich in/ab den Jahren 2009 bzw. 2010 ff.

In diesen news hat am 24.02.2009 CTT seit langem wieder ein Mal auf sich aufmerksam gemacht:

Fairfield, CT - (February 24, 2009) - Competitive Technologies, Inc. (NYSE Alternext US: CTT) announced today that it has signed an agreement with Life Epistéme srl granting them exclusive distribution rights in each of 29 countries throughout Europe, Asia, Africa, the Middle East, South America and Oceania for CTT's pain management medical device. The device is a non-invasive method for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs.
"We have seen this innovative device successfully used in Italy, and are proud to be able to bring it to other patients around the world," said Dr. Domenico Pecorini, one of the founders of Life Epistéme. "The population in the countries included in our contract totals over 1.7 billion people, about 25% of the world's population. Our network of distributors in strategic centers around the world will facilitate the delivery process for the device."
"Life Epistéme provides CTT with a strong and effective global partner," said John B. Nano, CTT's Chairman, President and CEO. "This represents a remarkable opportunity for our innovative pain management medical device. Our exclusive signed distribution agreements for this device now cover over 45% of the world's population and the contractual minimums have a retail sales value of over $25 million for 2009 and about $50 million for 2010. CTT will share in revenue derived from sales of the device to our distributors and both CTT and our distributors expect sales to exceed the contract minimums."

http://www.competitivetech.net/


><

immer noch nicht viel los hier................

[married]

Antwort auf Beitrag Nr.: 41.960.911 von alex63 am 16.08.11 21:25:03

alex schrieb am 16.08.2011:
nich viel los hier, seltsam

* * *

Du kamst ( wie so oft wieder ein Mal ) zu spät, denn

married schrieb am 04.05.10 13:42:35
Beitrag Nr.56 (39.451.820)
Beitrag versenden Beitrag melden Beitrag drucken Antwort Zitat Antwort auf Beitrag Nr.: 39.449.791 von lerchengrund am 04.05.10 09:41:03

" Da kann man Gewinne mitnehmen "

* * *





Nimm's leicht.